Helix BioPharma Corp. (TSX: HBP; OTC: HBPCF; Frankfurt: HBP0), a clinical-stage oncology company, has reported a net loss of $3,354,000 for the fiscal year ended July 31, 2026, down from $5,205,000 in the prior year. The loss per common share narrowed to $0.04 from $0.09, reflecting significantly reduced research and development spending. The company closed the year with cash reserves of $804,000 and a working capital deficiency of $4,181,000, underscoring ongoing liquidity pressures that investors may be watching closely.

Key Points

  • Helix BioPharma Corp. (TSX: HBP; OTC: HBPCF; Frankfurt: HBP0) is a clinical-stage oncology company developing therapies for difficult-to-treat cancers.
  • Net loss narrowed to $3,354,000 ($0.04 per share) for fiscal year ended July 31, 2026, compared with $5,205,000 ($0.09 per share) in fiscal 2025.
  • R&D expenses fell 54% to $1,620,000; cash reserves stood at $804,000 with an accumulated deficit of $219,230,000 as at July 31, 2026.
  • Investors may be watching the company's ability to secure bridge financing to support the planned Phase Ib/randomised Phase II study of L-DOS47 in NSCLC.

Helix BioPharma Fiscal 2026 Financial Results: Reduced Losses but Liquidity Concerns Persist

Helix BioPharma reported total operating expenses of $3,639,000 for fiscal 2026, compared with $5,397,000 in fiscal 2025. Research and development expenditures declined by $1,938,000, or 54%, to $1,620,000, primarily due to the wind-down of the LDOS006 pancreatic cancer study and deferred engagement with external service providers pending fundraising. Operating, general and administration expenses rose 10% to $2,019,000, driven by higher stock-based compensation and increased salaries. The company ended the year with shareholders' equity of $14,208,000 and an accumulated deficit of $219,230,000.

L-DOS47 NSCLC Program and LEUMUNA™ Research Option Extension

During fiscal 2026, Helix received positive written feedback from the US Food and Drug Administration on the study design for LDOS007, a planned Phase Ib/randomised Phase II study evaluating L-DOS47 in combination with pembrolizumab as first-line therapy in non-small cell lung cancer. A peer-reviewed article on a previously completed Phase I/II L-DOS47 monotherapy study was published in Frontiers in Oncology. The company also extended its Research and Exclusive Option Agreement with metaShape Pharma AG covering LEUMUNA™ through December 31, 2028, preserving its strategic optionality in metabolic indications.

Leadership Overhaul and Board Reconstitution at Helix BioPharma

Helix undertook substantial governance changes during fiscal 2026 and subsequent to year-end. The company appointed Karen Krumeich as Board Chair alongside three additional new directors, reconstituted its Audit Committee with three independent members, and added Markus Loeffler, MD, MBA, as Chief Medical Officer subsequent to year-end. Helen Middleton joined as General Counsel and David Browning as Vice President of Clinical Operations. CEO Thomas Mehrling was also appointed to the Board. Several directors resigned during the period, leaving a board of six, five of whom are independent.

Convertible Debentures and Failed $33.37 Million Equity Financing

In May 2026, Helix closed a non-brokered private placement of unsecured convertible debentures totalling $3,673,000, bearing interest at 25% per annum and maturing July 27, 2027, convertible at $1.42 per common share. A subscription agreement for $33,370,000 in equity financing signed in December 2025 did not close after the subscriber, Quantum Global Ventures AG, declared bankruptcy. The company states its cash of $804,000 is insufficient for the next twelve months and that securing additional financing remains of utmost importance to management.